

# Tetyana Tegnebratt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9239463/publications.pdf>

Version: 2024-02-01

7  
papers

67  
citations

1684188  
5  
h-index

1720034  
7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

105  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and preclinical evaluation of [11C]PAQ as a PET imaging tracer for VEGFR-2. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1283-1295.	6.4	25
2	Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches. EJNMMI Research, 2014, 4, 34.	2.5	9
3	[18F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models. EJNMMI Research, 2013, 3, 67.	2.5	8
4	<p></p>Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled Probe</p>. International Journal of Nanomedicine, 2020, Volume 15, 6137-6152.	6.7	8
5	[68Ga]ABY-028: an albumin-binding domain (ABD) protein-based imaging tracer for positron emission tomography (PET) studies of altered vascular permeability and predictions of albumin-drug conjugate transport. EJNMMI Research, 2020, 10, 106.	2.5	7
6	Treatment response assessment with (R)-[11C]PAQ PET in the MMTV-PyMT mouse model of breast cancer. EJNMMI Research, 2018, 8, 25.	2.5	6
7	Visualization of angiogenesis during cancer development in the polyoma middle T breast cancer model: molecular imaging with (R)-[11C]PAQ. EJNMMI Research, 2014, 4, 17.	2.5	4